Already boasting a positive recommendation overseas, Novo’s hemophilia A newcomer Frehemgo will have to wait a while longer ...

Attruby maker BridgeBio is re-upping its “Don’t Pass on Your Heart Health” campaign with a fresh new beat.  | BridgeBio's YouTube awareness push to lead up to World Amyloidosis Day features a ...

The FDA has warned Evolus over an Instagram reel that made the “especially problematic” suggestion of blurred lines between a ...

For biopharmaceutical commercial teams, integrating clinical support into Patient Support Programs (PSPs) is becoming a ...

Eli Lilly’s Jaypirca, the first noncovalent BTK inhibitor, has won FDA approval for the first-line treatment of chronic ...

Following a spate of large-scale pharma investments in the U.S. last year, German conglomerate Bayer is advancing its own plans to expand in America, in a move the company is framing as the ...

Pfizer is making moves on the dermatology and wider immunology fronts, detailing two phase 3 wins for its oral Janus kinase inhibitor, Litfulo, and a promising phase 2 update for its investigationa | ...

With GLP-1s paving the way, a consumer shift is happening across markets for certain branded pharmaceuticals. | With GLP-1s ...

Already sharing the load on two biosimilar assets, Teva Pharmaceutical and Samsung Bioepis have elected to take their ...

In three deals each worth $2 billion or more, AstraZeneca is investing in Summit Therapeutics with a focus on ivonescimab and ...

Genentech is turning up the volume on breast cancer conversations in its “About Damn Time” campaign with Breastcancer.org and ...

While Foundayo’s insulin-matching potential in type 2 diabetes had been established in a topline readout earlier this year, ...